**Wake Forest NCORP Research Base**

**Bi-Weekly Broadcast**

**February 18, 2020**

**WAKE NCORP Website link** <https://wakencorp.phs.wakehealth.edu/>



**NEW TRAVEL AWARDS FOR PRIORITY ACCRUALS in 2020:**

The Wake Forest NCORP Research Base will offer travel awards to cover two nights hotel accommodations at the Wake Forest NCORP 2020 Annual Meeting for NCORP Community and M/U Community sites that accrue the highest number of racial/ethnic minority (WF 10217 & WF 1802) and rural patients (WF 30917CD), see below. Two travel awards per study will be offered for each of the following protocols:

* TELEHEALTH: WF 30917CD (all accruals between 1/1/2020 and 8/31/2020)
* PCW: WF 1802 (all accruals to AA and/or low-income strata between 1/1/2020 and 8/31/2020)
* WAYS: WF 10217 (all accruals between 1/1/2020 and 5/31/2020)

**STUDY UPDATES:**

* **NEW – WF 1805CD HN Star *– Implementation and Effectiveness Trial of HN-STAR*** 
  + An Introductory WebEx will be held February 25 at 3pm. If you did not receive a WebEx invitation, please contact us at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).
* **WF-1803CD-CAREGIVERS**

**\*\*\*Complete the rostering survey for enrollment by March 18, 2020\*\*\***

* + If you would like to participate in this study, please start the rostering process before this date. If you have any questions regarding this process, please contact [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu)

[WF1803CD - Practice Group Rostering and Component/Subcomponent Eligibility & Registration](https://redcap.wakehealth.edu/redcapccc/surveys/?s=WPMTHP8A3N)

* + Data collection for this study will end on or around April 30, 2020.
* **WF 1801 Ramipril – *A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy***
  + Chemotherapy drugs should not be reported on the concomitant medications form in REDCap. There is a place to report if all temozolomide was taken as prescribed for that time period on the weekly assessments during titration and during Radiation Therapy (RT).
* **WF 1806 M&M – *Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer.***


Looking for a study for older patients? What about Spanish speaking patients?

Who can participate?


* + Older adults (age ≥ 65y) with either
    - Newly diagnosed metastatic CRC or
    - newly recognized metastatic recurrence of CRC greater than 1 year from completion of treatment for non-metastatic CRC
  + Planning to undergo 1st line 5-FU based chemotherapy as monotherapy or combination.

What is involved?

* + 3 Time points: Baseline, Time point 1 & Time point 2
  + Capturing data on routine treatment, labs & Grade 3 or higher Toxicities.
  + Brief physical testing – SPPB and HGS
  + Patient will complete paper surveys at each timepoint (approx. 20 mins)
  + Submission of patient blood for DNA markers & routine CT images
  + Survival status captured at 1 year from diagnosis




* + **Interested? Email** [**NCORP@wakehealth.edu**](mailto:NCORP@wakehealth.edu) **for a start-up packet now!**
  + The FAQ document for this study was revised on January 31, 2020 and has been posted on the WAKE NCORP website.
* **WF 1802 PCW – *Influence of Primary Treatment for Prostate Cancer on Work Experience***
  + The **Moderate to High Income, White** stratum is nearing closure with less than 5 slots remaining.
  + You can determine the remaining slots left for any stratum by going to **CTSU-OPEN** -> **Slot Reservation** -> **Report**. Please see screenshot below.



* + This study compares changes in work ability reported by African American and white prostate cancer survivors with higher and lower incomes. If you would like for the **Wake Forest Health Equity Core team** to contact you regarding ideas to help increase recruitment of African American and low income participants, please email [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).
* **WF 98213 PREVENT – *Preventing Anthracycline Cardiovascular Toxicity with Statins***
  + Reminder for those that may have patients coming back in for their 24 month follow-up, please make sure to schedule, remind your patients of this important visit, collect the data and send data into [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) .

**REDCap Data Queries…AKA “Resolve Issues”**

Please remember to click the “Resolve Issues” button in REDCap on the toolbar on the left side in the Applications section to see if you have any data queries.



**General Site email address**: If your site has a general email address that you would like for WF NCORP RB to use in order to assure that your site gets all of the Bi-Weekly and Special Broadcasts, please send that email along with your site name and CTEP ID to [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).

**General Biospecimen Lab Management:**

* Please request your lab kits before you run completely out of kits. This will ensure that there will be no delay in getting samples shipped to the Biospecimen Laboratory.
* Please do not ship samples on Thursday or Friday so that samples do not arrive on a weekend.
* **Accruals as of February 14, 2020**

|  |  |  |  |
| --- | --- | --- | --- |
| **Open Studies** | **Name** | **Enrolled** | **Target** |
| WF 97115 | Acupuncture | 209 | 240 |
| WF 97116 | Remember | 242 | 276 |
| WF 97415 | Upbeat | 245 | 1000 |
| WF 10217 | Ways | 206 | 220 |
| WF 1801 | Ramipril | 26 | 75 |
| WF 1802 | PCW | 68 | 220 |
| WF 20817CD | OaSiS | 1,076 | 1114 |
| WF 30917CD | Telehealth | 30 | 90 |
| WF 1803CD | Caregivers | 611 | 828 |
| WF 1804CD | AH-HA | 0 | 624 |
| WF 1806 | M&M | 12 | 300 |
| EAQ161CD | Biomarker Survey | 54 | 201 |